

**IN THE SPECIFICATION:**

Please amend the specification as follows:

After the "Description of the figures" on page 36, please insert the following:

FIG. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of a specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1). The abbreviations have the following meaning:

mock, con.	=	treatment group 1
mock + VEGF-A	=	treatment group 2
sTIE2-cl13	=	treatment group 3
sTIE2-cl13 + VEGF-A	=	treatment group 4

—◇— mock, con. —◆— mock+VEGF-A.. —▲— sTIE2-cl13 —▲— sTIE2-cl13+VEGF-A.

---